Correspondence 0001104659-25-011487 from Ocugen, Inc. (OCGN) (CIK 0001372299) (OCGN)
Ocugen, Inc. (OCGN) (CIK 0001372299)
Date: Feb. 11, 2025 · CIK: 0001372299 · Accession: 0001104659-25-011487
AI Filing Summary & Sentiment
File numbers found in text: 333-284629
Letter
Ocugen, Inc.
11 Great Valley Parkway
Malvern, PA 19355
February 11, 2025
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Ocugen, Inc.: Registration Statement on Form S-3 filed January 31, 2025 (File No. 333-284629)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ocugen, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 13, 2025 at 4:30 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Jennifer Porter of Goodwin Procter LLP at (445) 207-7806.
Sincerely,
Ocugen, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Ocugen, Inc.
11 Great Valley Parkway
Malvern, PA 19355
February 11, 2025
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Ocugen, Inc.: Registration Statement on Form S-3 filed January 31, 2025 (File
No. 333-284629)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”), Ocugen, Inc. (the “Company”) hereby requests that the
effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 13,
2025 at 4:30 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by
telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company
acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request,
please contact Jennifer Porter of Goodwin Procter LLP at (445) 207-7806.
Sincerely,
Ocugen, Inc.
/s/ Shankar Musunuri
Shankar Musunuri, Ph.D., MBA
Chief Executive Officer and Chairman
cc:
Ramesh Ramachandran, Ocugen, Inc.
Rachael Bushey, Esq., Goodwin Procter
LLP
Jennifer Porter, Esq., Goodwin Procter
LLP
Jesse Fishman, Esq., Goodwin Procter LLP